Merck Says Subcutaneous Pembrolizumab Met Primary Endpoints in Phase 3 Trial

MT Newswires Live03-27

Merck (MRK) said Thursday that a phase 3 trial evaluating subcutaneous pembrolizumab together with berahyaluronidase alfa met the study's primary endpoints, as pembrolizumab administered with chemotherapy demonstrated noninferior pharmacokinetics compared with intravenous Keytruda combined with chemotherapy.

Subcutaneous pembrolizumab also showed consistent results for objective response rate, progression-free survival, duration of response and safety, according to the company.

The company said the US Food and Drug Administration has accepted a biologics license application to review subcutaneous pembrolizumab across all previously approved solid tumor indications for Keytruda and set a target action date of Sept. 23.

The European Medicines Agency also validated an extension application for the new pharmaceutical form and new route of administration of Keytruda, Merck said.

Price: 88.09, Change: -0.03, Percent Change: -0.03

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment